SCHEMBL4241373

SCHEMBL4241373

CCN(CC)CCn1cnc2ccc(C=C3SC(Nc4c(Cl)cccc4Cl)=NC3=O)cc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CISD1 Q9NZ45 1/20 0.38
HTR6 P50406 1/20 0.37
ENPP2 Q13822 1/20 0.35
SRC P12931 7/20 0.34
FGFR1 P11362 6/20 0.34
IKBKB O14920 2/20 0.34
CHUK O15111 1/20 0.34
MAPK13 O15264 1/20 0.34
LCK P06239 1/20 0.34
LYN P07948 1/20 0.34
ZAP70 P43403 1/20 0.34
MAPK12 P53778 1/20 0.34
BTK Q06187 1/20 0.34
MAPK11 Q15759 1/20 0.34
MAPK14 Q16539 1/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
ALOX5 P09917 2/20 0.32
NPC1 O15118 1/20 0.32
TNNI3 P19429 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4241371 1.00 CISD1 (0.38) CISD1HTR6ENPP2SRCFGFR1
SCHEMBL4237292 0.92 HTR6 (0.44) CISD1HTR6ENPP2LCKMEN1
SCHEMBL4237297 0.92 HTR6 (0.44) CISD1HTR6ENPP2LCKMEN1
SCHEMBL4241884 0.91 CISD1 (0.36) CISD1HTR6ENPP2SRCFGFR1
SCHEMBL4241880 0.91 CISD1 (0.36) CISD1HTR6ENPP2SRCFGFR1
SCHEMBL4240663 0.87 HSD17B13 (0.39) CISD1HTR6ENPP2MEN1KMT2A
SCHEMBL4240664 0.87 HSD17B13 (0.39) CISD1HTR6ENPP2MEN1KMT2A
SCHEMBL4242457 0.85 HDAC1 (0.40) CISD1ENPP2MEN1KMT2AHDAC1
SCHEMBL4242454 0.85 HDAC1 (0.40) CISD1ENPP2MEN1KMT2AHDAC1
SCHEMBL4245447 0.85 LMNA (0.38) CISD1HTR6ENPP2PIM1PIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048252-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-02-19 US claimed
EP-1993536-A2 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SmithKline Beecham Corporation (US) 2008-11-26 EP claimed
US-20070249599-A1 Novel Chemical Compounds DUFFY KEVIN J 2007-10-25 US claimed
WO-2007103755-A2 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-09-13 WO claimed
EP-1718642-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-08 EP claimed
WO-2005082901-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-09 WO claimed
US-20090048252-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-02-19 US disclosed
EP-1993536-A2 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SmithKline Beecham Corporation (US) 2008-11-26 EP disclosed
US-20070249599-A1 Novel Chemical Compounds DUFFY KEVIN J 2007-10-25 US disclosed
WO-2007103755-A2 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-09-13 WO disclosed
EP-1718642-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-08 EP disclosed
WO-2005082901-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249599-A1 Novel Chemical Compounds HIPK3, HIPK1, HIPK4 CISD1 2650/4885HTR6 3737/4885ENPP2 1265/4885
US-20090048252-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS PIK3CA, BTK, PI4KA CISD1 4327/4885HTR6 1179/4885ENPP2 562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.